Some recent trial results confirm that Intendis are moving forward with the development of Finacea Foam.
The summary of a recent trial, quoted in Skin and Allergy News shows that Finacea Foam is more effective at reducing rosacea symptoms compared to the inactive vehicle.
This trial doesn’t show whether Finacea Foam is more effective than Finacea Gel, but does suggest that Finacea Foam likely to become an viable alternative treatment.
Do We Need Finacea Foam?
It seems clear that Intendis wants to expand the number of products it manufactures to treat rosacea. This makes sense from the point of view of the company; another potential revenue stream and more products appear in your portfolio.
But what about rosacea sufferers – should they be excited about Finacea Foam? Well that is yet to be seen. It seems unlikely to me that a mineral oil based emulsion, such as is common in foaming products, will offer too many options to still-wanting rosacea sufferers. Time will tell.
Investigational Azelaic Acid Foam Quells Rosacea
11/17/11
FROM THE ANNUAL CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Medical Dermatology
By: BRUCE JANCIN, Skin & Allergy News Digital Network
LISBON – Physicians may soon have a new option for the treatment of papulopustular rosacea in the form of 15% azelaic acid foam.
The 15% foam is an extension of an existing product line which includes 15% azelaic acid gel as an approved topical therapy for mild to moderate rosacea, Dr. Blanka Havlickova explained at the annual congress of the European Academy of Dermatology and Venereology.
Major Finding: In all, 43% of patients with papulopustular rosacea were rated as clear or as having minimal residual disease after 12 weeks of twice-daily, topical, 15% azelaic acid foam therapy.
Data Source: A double-blind, vehicle-controlled, randomized clinical trial of 401 patients with mild to moderate papulopustular rosacea who were randomized to 12 weeks of twice-daily, self-applied azelaic acid foam or vehicle.
Disclosures: The trial was funded by Intendis, which is developing the investigational agent.
